期刊
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
卷 69, 期 2, 页码 129-138出版社
OXFORD UNIV PRESS INC
DOI: 10.1097/NEN.0b013e3181ca4767
关键词
Astrocytoma; beta III-tubulin; Diagnostic marker; Glioblastoma; Immunohistochemistry; Neuronal marker; PROX1
资金
- Swedish Cancer Society
- Swedish Research Council-Medicine
- Swedish Childhood Cancer Foundation
- Cancer Society in Stockholm
- Karolinska Institutet
- Karolinska University Hospital
- Ake Wiberg's Foundation
- Magnus Bergvall's Foundation
PROX1 is a prospero-related transcription factor that plays a critical role in the development of various organs including the mammalian lymphatic and central nervous systems; it controls cell proliferation and differentiation through different transcription pathways and has both oncogenic and tumor-suppressive functions. We investigated PROM expression patterns in 56 human astrocytic gliomas of different grades using immunohistochemistry. An average of 79% of cells in World Health Organization Grade IV (glioblastoma, n = 15) and 57% of cells in World Health Organization Grade III (anaplastic astrocytoma, n = 13) were strongly PROX1 positive; low-grade diffuse astrocytomas (Grade 11, n = 13) had 21% of cells that were strongly positive; Grade I tumors (n = 15) had 1.5%; and non-neoplastic brain tissue (n = 15) had 3.7% of cells that were PROX1 positive. Double immunolabeling showed that PROX1+ cells in glioblastomas frequently coexpressed early neuronal proteins MAP2 and beta III-tubulin but not the mature neuronal marker protein NeuN. Analyses of coexpression with proliferation markers suggest that PROX1+ cells have a marginally lower rate of proliferation than other turner cells but are still mitotically active. We conclude that PROX1 may constitute a useful tool for the diagnosis and grading of astrocytic gliomas and for distinguishing Grade III and Grade IV tumors from Grade I and Grade II tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据